Antimalarials should target female parasites


Disease causing organisms are notorious for their rapid evolution and their quick aquisition of resistance to the drugs used to fight them. However, in the case of the disease causing parasites Plasmodium, scientists have shown that it is the males of the species that really race ahead in the evolutionary race.

Sex is a key driver for evolution but this tends to be overlooked when looking at unicellular life forms, said Sarah Reece of Edinburgh University and her colleagues in their paper. The Plasmodium parasite, unlike humans, for example, does not have different genes coding for different sexes. Instead, sex is solely determined by which genes are expressed. Reece and colleagues placed the parasites under evolutionary pressure and observed that it was the male-biased genes that were the fast adaptors. The finding suggests that to help prevent resistance, new antimalarials should target the slower evolving female genes, or those that are expressed by both sexes.


Related Content

New antimalarial drug class resists resistance

21 March 2013 Research

news image

Drug candidate looks promising as scientists draw on past failures to address toxicity problems

Chemistry World podcast - May 2013

2 May 2013 Podcast | Monthly

news image

Robert Lovitt tells us about algae biotechnology, Patrick Holland discusses nitrogen fixing chemistry and the team cover the ...

Most Read

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

Isotope effect produces new type of chemical bond

22 October 2014 Research

news image

Evidence emerges for vibrational bond first proposed 30 years ago

Most Commented

Higher levels of some metals in e-cigarette smoke

8 September 2014 Research

news image

Scientists call for regulators to help clear smoke and mirrors surrounding vaping safety

US agency fast-tracks Ebola vaccine development

23 October 2014 News and Analysis

news image

Health and Human Services invests almost $6 million to ready an Ebola vaccine candidate for clinical trials, meanwhile GSK sa...